| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 蛋白的配体-介导的共价修饰 | CN201080064972.7 | 2010-12-30 | CN102812167A | 2012-12-05 | 拉塞尔·C·彼得; 查尔斯·F·杰维尔; 李广镐; 阿拉温德·普拉萨德·麦迪康达; 牛德强; 乔立新; 尤斯温德·辛格; 振东·朱 |
| 本发明涉及酶抑制剂。更具体而言，本发明涉及蛋白的配体-介导的共价修饰；其设计方法；其药物制剂；及其使用方法。 | ||||||
| 2 | 用于核苷酸突变鉴定的探针组及用于核苷酸突变鉴定的方法 | CN201080027543.2 | 2010-04-22 | CN102459640A | 2012-05-16 | 岸安宏; 神谷直洋 |
| 可通过使用包含检测探针和反向探针的探针组进行荧光实时PCR来鉴定位于靶核酸突变位点的核苷酸的类型，其中检测探针包括寡核苷酸，该寡核苷酸包括含在靶核酸上的突变位点以及突变位点中还包含所关注的核苷酸的核苷酸序列、或与前述核苷酸序列互补的核苷酸序列，所述寡核苷酸具有添加到5’末端的荧光物质和添加到3’末端的猝灭物质，并具有引入其中的修饰，该修饰使所述探针的解链温度变得比反向探针的解链温度高3℃以上，并且其中反向引物包括寡核苷酸，该寡核苷酸包括含突变位点以及突变位点中还包含与所关注的核苷酸不同的核苷酸的核苷酸序列、或与前述核苷酸序列互补的核苷酸序列。 | ||||||
| 3 | HCV PROTEASE INHIBITORS AND USES THEREOF | US14010892 | 2013-08-27 | US20130338062A1 | 2013-12-19 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 4 | PROBE SET FOR IDENTIFICATION OF NUCLEOTIDE MUTATION, AND METHOD FOR IDENTIFICATION OF NUCLEOTIDE MUTATION | US13278288 | 2011-10-21 | US20120095116A1 | 2012-04-19 | Yasuhiro KISHI; Naohiro Kamiya |
| A probe set comprising a detection probe and a counter probe, wherein the detection probe comprises an oligonucleotide which comprises a nucleotide sequence containing the mutation site on the target nucleic acid and also containing a nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence, has a fluorescent substance added to the 5′-terminal and a quenching substance added to the 3′-terminal, and has, introduced therein, such a modification that the melting temperature of the probe becomes 3° C. or more higher than that of the counter probe, and wherein the counter probe comprises an oligonucleotide which comprises a nucleotide sequence containing a mutation site and also containing a nucleotide that is different from the nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence. | ||||||
| 5 | 塩基変異判別用プローブセットおよび塩基変異の判別方法 | JP2011510354 | 2010-04-22 | JPWO2010123058A1 | 2012-10-25 | 安宏 岸; 直洋 神谷 |
| 標的核酸上の変異部位を含む塩基配列であって該変異部位に目的の塩基を含む塩基配列、または該塩基配列に相補的な塩基配列を有し、5'末端に蛍光物質が、3'末端に消光物質が付加され、さらにプローブの融解温度がカウンタープローブの融解温度よりも3℃以上高くなるような修飾が導入されたオリゴヌクレオチドからなる検出用プローブと、変異部位を含む塩基配列であって該変異部位に前記目的の塩基とは異なる塩基を含む塩基配列、または該塩基配列に相補的な塩基配列を有するオリゴヌクレオチドからなるカウンタープローブと、を含むプローブセットを用いて蛍光リアルタイムPCRを行い、標的核酸の変異部位における塩基の種類を特定する。 | ||||||
| 6 | Ligand of protein - directional covalent modification | JP2012547291 | 2010-12-30 | JP2013516422A | 2013-05-13 | シー． ペッター ラッセル; エフ． ジェウエル チャールズ; リー クワングホ; プラサド メドイコンダ アラビンド; ニウ デクイアング; クイアオ リクイン; シングフ ジャスウィンダー; ズフ ズヘンドング |
| 本発明は、酵素インヒビターに関する。 より詳細には、本発明は、タンパク質のリガンド-指向性共有的修飾；それをデザインする方法；それの医薬製剤；及び、使用方法に関する。
【選択図】図1 |
||||||
| 7 | DEGRON FUSION CONSTRUCTS AND METHODS FOR CONTROLLING PROTEIN PRODUCTION | EP16818587.4 | 2016-06-28 | EP3313863A2 | 2018-05-02 | LIN, Michael, Z.; CHUNG, Hokyung; JACOBS, Conor |
| Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a czs-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired. | ||||||
| 8 | HCV PROTEASE INHIBITORS AND USES THEREOF | US15222592 | 2016-07-28 | US20160326216A1 | 2016-11-10 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 9 | HCV protease inhibitors and uses thereof | US14010892 | 2013-08-27 | US08980935B2 | 2015-03-17 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 10 | HCV protease inhibitors and uses thereof | US12541347 | 2009-08-14 | US08188137B2 | 2012-05-29 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 11 | HCV PROTEASE INHIBITORS AND USES THEREOF | US12541347 | 2009-08-14 | US20100041674A1 | 2010-02-18 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 12 | DEGRON FUSION CONSTRUCTS AND METHODS FOR CONTROLLING PROTEIN PRODUCTION | US15737712 | 2016-06-28 | US20180179509A1 | 2018-06-28 | Michael Z. LIN; Hokyung CHUNG; Conor JACOBS |
| Engineered fusion proteins comprising a self-excising degron for controlling protein production are disclosed. In particular, the inventors have constructed fusion proteins comprising a degron connected to a protein of interest through a cleavable linker comprising a hepatitis C virus (HCV) protease site. The degron can be removed from the protein of interest by a czs-encoded HCV protease such that the protein of interest can be produced with minimal structural modification. Clinically available HCV protease inhibitors can be used to block protease cleavage such that the degron is retained after inhibitor addition on subsequently synthesized protein copies. The degron when attached causes rapid degradation of the linked protein. Such fusions of a degron to a protein of interest will be especially useful when control over protein production with minimal structural modification is desired. | ||||||
| 13 | Ligand-Directed Covalent Modification of Protein | US15423115 | 2017-02-02 | US20170218353A1 | 2017-08-03 | Russell C. Petter; Charles F. Jewell; Kwangho Lee; Aravind Prasad Medikonda; Deqiang Niu; Lixin Qiao; Juswinder Singh; Zhendong Zhu |
| The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use. | ||||||
| 14 | HCV protease inhibitors and uses thereof | US14639228 | 2015-03-05 | US09422333B2 | 2016-08-23 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 15 | HCV PROTEASE INHIBITORS AND USES THEREOF | US14639228 | 2015-03-05 | US20150175657A1 | 2015-06-25 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Signh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 16 | HCV protease inhibitors and uses thereof | US13443847 | 2012-04-10 | US08524760B2 | 2013-09-03 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 17 | HCV PROTEASE INHIBITORS AND USES THEREOF | US13443847 | 2012-04-10 | US20120190614A1 | 2012-07-26 | Deqiang Niu; Russell C. Petter; Lixin Qiao; Juswinder Singh |
| The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | ||||||
| 18 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | US12982352 | 2010-12-30 | US20110269244A1 | 2011-11-03 | Russell C. Petter; Charles F. Jewell; Kwangho Lee; Aravind Prasad Medikonda; Deqiang Niu; Lixin Qiao; Juswinder Singh; Zhendong Zhu |
| The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use. | ||||||
| 19 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | EP10841710 | 2010-12-30 | EP2519664A4 | 2014-03-12 | PETTER RUSSELL C; JEWELL CHARLES F; LEE KWANGHO; MEDIKONDA ARAVIND PRASAD; NIU DEQIANG; QIAO LIXIN; SINGH JUSWINDER; ZHU ZHENDONG |
| The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use. | ||||||
| 20 | PROBE SET FOR IDENTIFICATION OF NUCLEOTIDE MUTATION, AND METHOD FOR IDENTIFICATION OF NUCLEOTIDE MUTATION | EP10767115 | 2010-04-22 | EP2423324A4 | 2013-02-13 | KISHI YASUHIRO; KAMIYA NAOHIRO |
| The type of a nucleotide located in a mutation site on a target nucleic acid can be identified by carrying out a fluorescence real-time PCR using a probe set comprising a detection probe and a counter probe, wherein the detection probe comprises an oligonucleotide which comprises a nucleotide sequence containing the mutation site on the target nucleic acid and also containing a nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence, has a fluorescent substance added to the 5'-terminal and a quenching substance added to the 3'-terminal, and has, introduced therein, such a modification that the melting temperature of the probe becomes 3°C or more higher than that of the counter probe, and wherein the counter probe comprises an oligonucleotide which comprises a nucleotide sequence containing a mutation site and also containing a nucleotide that is different from the nucleotide of interest in the mutation site or a nucleotide sequence complementary to the aforementioned nucleotide sequence. | ||||||
QQ群二维码
意见反馈
意见反馈